Genentech, a Roche (RHHBY.PK) subsidiary, says the FDA has expanded the approved indication for...

|By:, SA News Editor

Genentech, a Roche (RHHBY.PK) subsidiary, says the FDA has expanded the approved indication for Actemra for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs. The drug can be used both alone as a single-agent therapy and in combination with other treatments.